Article Text

Download PDFPDF
Clinical evaluation of hsPR3-ANCA ELISA for detection of antineutrophil cytoplasmatic antibodies directed against proteinase 3
  1. J U Holle1,
  2. E Csernok1,
  3. G Fredenhagen2,
  4. M Backes1,
  5. J P Bremer1,
  6. W L Gross1
  1. 1
    Universitätsklinikum Schleswig-Holstein, Campus Lübeck, Department of Rheumatology and Klinikum Bad Bramstedt, Department of Rheumatology and Immunology, Lübeck, Germany
  2. 2
    Orgentec Diagnostika GmbH, Mainz, Germany
  1. Correspondence to Dr J U Holle, Universitätsklinikum Schleswig-Holstein, Campus Lübeck, Department of Rheumatology and Klinikum Bad Bramstedt, Department of Rheumatology and Immunology, Ratzeburger Allee 160, 23538 Lübeck, Germany; Julia.Holle{at}uk-sh.de

Statistics from Altmetric.com

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Antineutrophil cytoplasmatic antibodies (ANCA) are used as a diagnostic marker for Wegener’s granulomatosis (WG), microscopic polyangiitis (MPA) and Churg-Strauss syndrome (CSS), as high levels of ANCA are found in these conditions. Consensus guidelines currently recommend performing an immunofluorescence test (IFT) together with an ELISA to detect the ANCA pattern and the target antigen.1 Conventional ELISAs using proteinase 3 (PR3) immobilised to the surface of the ELISA plate show great variations in performance and often lack sensitivity.2 Capture ELISA is superior in overall diagnostic performance to direct ELISA,2 but the sensitivity of capture ELISA may be reduced by the capturing antibodies hiding relevant epitopes. hsPR3-ANCA ELISA immobilises PR3 …

View Full Text

Footnotes

  • Competing interests GF is an employee of Orgentec.

  • Provenance and Peer review Not commissioned; externally peer reviewed.